Investigational

Therapies

Our team strives to advance medicines for neurological,
neuroendocrine, and neuropsychiatric disorders.

 
Female doctor talking to father and son

We relentlessly pursue scientific discovery and development that can lead to important therapies for patients who desperately need new, better options.

Movement Disorders

  • valbenazine* for chorea in Huntington disease (HD)

    Valbenazine* is an investigational, selective, orally active vesicular monoamine transporter 2 (VMAT2) inhibitor for the potential treatment of chorea in HD.

    Learn More >

    Clinical Studies

    KINECT-HD2

    valbenazine* for dyskinetic cerebral palsy (DCP)

    Valbenazine* is an investigational, selective vesicular monoamine transporter 2 (VMAT2) inhibitor for the potential treatment of DCP.

    Learn More >

    Clinical Studies

    NBI-98854-DCP3018
    KINECT-DCP

Epilepsy

  • NBI-827104 for epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS)

    NBI-827104 is a selective, and brain penetrating T-type calcium channel blocker (Cav 3.1, Cav 3.2, Cav 3.3) for the potential treatment of EE-CSWS.

    Learn More >

    Clinical Studies

    STEAMBOAT

  • NBI-921352 for SCN8A developmental and epileptic encephalopathy (SCN8A-DEE)

    NBI-921352 is an investigational, selective sodium channel inhibitor (Nav1.6) for the potential treatment of SCN8A-DEE.

    Learn More >

    Clinical Studies

    KAYAK

    NBI-921352 for focal onset seizures in adults (FOS)

    NBI-921352 is an investigational, selective sodium channel inhibitor (Nav1.6) for the potential treatment of focal onset seizures in adults.

    Learn More >

    Clinical Studies

    NBI-921352-FOS2021

Congenital Adrenal Hyperplasia

  • crinecerfont for congenital adrenal hyperplasia (CAH)

    Crinecerfont is an investigational, oral, non-steroidal, selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist for the potential treatment of CAH due to 21-hydroxylase deficiency (21-OHD) in children and adults.

    Learn More >

Neuropsychiatric Disorders

  • valbenazine* as an add-on treatment for schizophrenia

    Valbenazine is an investigational, selective vesicular monoamine transporter 2 (VMAT2) inhibitor being developed as a potential add-on treatment for patients with schizophrenia.

    Learn More >

    Clinical Studies

    Journey Study

  • NBI-1065846§ for anhedonia in major depressive disorder (MDD)

    NBI-1065846§ is a potential first-in-class, investigational G protein-coupled receptor 139 (GPR139) agonist for the potential treatment of anhedonia in major depressive disorder (MDD).

    Learn More >

    Clinical Studies

    TERPSIS

  • NBI-1065845§ for inadequate response to treatment in major depressive disorder (MDD)

    NBI-1065845§ is a potential first-in-class, investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) potentiator for the potential treatment of patients with inadequate response to treatment in MDD.

    Learn More >

    Clinical Studies

    SAVITRI

  • luvadaxistat§ for cognitive impairment associated with schizophrenia (CIAS)

    Luvadaxistat§ is a potential first-in-class, investigational, selective d-amino acid oxidase (DAAO) inhibitor for the potential treatment of cognitive impairment associated with schizophrenia (CIAS).

    Learn More >

    Clinical Studies

    ERUDITE

  • NBI-1117568 for schizophrenia

    NBI-1117568 is an oral, investigational muscarinic M4 agonist for the potential treatment of schizophrenia.

    Learn More >

    Clinical Studies

    Phase 2 study

  • NBI-1070770§ for major depressive disorder (MDD)

    Neurocrine Biosciences has initiated a Phase 1 clinical study with NBI-1070770§, a novel, orally active, small molecule as a potential treatment for major depressive disorder.

    Learn More >

Neurocrine Biosciences has global rights unless otherwise noted. Neurocrine Biosciences shares profits and losses on NBI-1065845 and NBI-1065846 with Takeda Pharmaceutical Company Limited.
*Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and other select Asian markets.
Licensed from Idorsia Ltd.
Licensed from Xenon Pharmaceuticals, Inc.
§Licensed from Takeda Pharmaceutical Company Limited.
Licensed from Sosei Heptares.
A man and women investor listening in a meeting